Misuse and abuse of topical steroids: Implications

Expert Review of Dermatology

Volumn 2, Issue 1, 2007, Pages 31-40

  Nnoruka, Edith N ^a   Daramola, Olaniyi om ^b   Ike, Samuel O ^a  

^a UNIVERSITY OF NIGERIA   (Nigeria)

^b UNIVERSITY OF ILORIN   (Nigeria)

Author keywords

abuse; adverse events; burden; misuse; optimal administration; topical corticosteroids

Indexed keywords

EID: 84979002121     PISSN: 17469872     EISSN: 17469880     Source Type: Journal    
DOI: 10.1586/17469872.2.1.31     Document Type: Article

References (47)

1. Brazzini B, Pimpinelli N. New and established topical corticosteroids in dermatology: clinical pharmacology and therapeutic use. Am. J. Clin. Dermatol. 3 (1), 47–58 (2002).
2. Smith EW. Do we need new and different glucocorticoids? A re-appraisal of the various congeners and potential alternatives. Curr. Probl. Dermatol. 21, 1–10 (1993).
3. Ljubojeviae S, Basta-Juzbasiae A, Lipozeneiae J. Steroid dermatitis resembling rosacea: aetiopathogenesis and treatment. J. Eur. Acad. Dermatol. Venereol. 16 (2), 121–126 (2002).
4. Yohn JJ, Weston WL. Topical glucocorticosteroids. Curr. Probl. Dermatol. 2, 31–63 (1990).
5. Vickers CF. Existence of reservoir in the stratum corneum: experimental proof. Arch. Dermatol. 88, 20–22 (1963).
6. Feldmann RJ, Maibach HI. Regional variation in percutaneous penetration of 14c cortisol in man. J. Invest. Dermatol. 48, 181–183 (1967).
7. Sulzberger MB, Whitten VH. Effect of topically applied compound F in selected dermatoses. J. Invest. Dermatol. 19, 101–102 (1952).
8. Miller JA, Munro DD. Topical corticosteroids: clinical pharmacology and therapeutic use. Drugs 19 (2), 119–134 (1980).
9. Fusaro RM, Kingsley DN. Topical glucocorticoids: how they are used and misused. Postgrad. Med. 79, 283–291 (1986).
10. Lagos BR, Maibach HI. Frequency of application of topical corticosteroids: an overview. Br. J. Dermatol. 139, 763–766 (1998).
11. Thalen A, Brattsand R, Andersson PH. Development of glucocorticosteroids with enhanced ratio between topical and systemic effects. Acta. Derm. Venereol. (Stockh.) 69 (Suppl. 151), 11–19 (1989).
12. Schacke H, Schottelius A, Docke WD et al. Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects. Proc. Natl Acad. Sci. USA 10, 227–232 (2004).
13. Gibson JR, Kirsch J, Darley CR. An assessment of the relationship between vasoconstrictor assay findings, clinical efficiency and thinning effects of a variety of undiluted and diluted corticosteroid preparations. Br. J. Dermatol. 111 (Suppl. 27), 204–212 (1984).
14. Coopman S, Degreef H, Dooms-Goossens A. Identification of cross-reaction patterns in allergic contact dermatitis from TCS. Br. J. Dermatol. 121, 27–34 (1989).
15. Sterry W. Therapy with topical corticosteroids. Arch. Dermatol. Res. 284 (1), S27 –S29 (1992).
16. Wojas-Pelc A, Setkowicz M, Bogdaszewska-Czabanowska J, Katedra I. Topical corticosteroids in dermatology – advantages and side effects. Przegl. Lek. 59 (3), 70–74 (2002).
17. du Vivier A. Tachyphylaxis to topically applied steroids. Arch. Dermatol. 112 (9), 1245–1248 (1976).
18. Eisen D, Carrozzo M, Bagan Sebastian JV, Thongprasom K. Oral lichen planus: clinical features and management. Oral Dis. 11 (6), 338–349 (2005).
19. Scully C, Gorsky M, Lozada-Nur F. Aphthous ulcerations. Dermatol. Ther. 15, 85 (2002).
20. Mucha SM, Baroody FM. Sinusitis update. Curr. Opin. Allergy Clin. Immunol. 3, 33–38 (2003).
21. Pullerits T, Praks L, Ristioja V, Lotvall J. Comparison of a nasal glucocorticoid, antileukotriene, and a combination of antileukotriene and antihistamine in the treatment of seasonal allergic rhinitis. J. Allergy Clin. Immunol. 109 (6), 949–955 (2002).
22. Gionchetti P, D’Arienzo A, Rizzello F et al. Topical treatment of distal active ulcerative colitis with beclomethasone dipropionate or mesalamine: a single-blind randomized controlled trial. J. Clin. Gastroenterol. 39 (4), 291–297 (2005).
23. Yang SS, Tsai YC, Wu CC, Liu SP. Highly potent and moderately potent topical steroids are effective in treating phimosis: a prospective randomized study. J. Urol. 173 (4), 1361–1363 (2005).
24. Ohman EM, Rogers S, Meenan FO, McKenna TJ. Adrenal suppression following low-dose topical clobetasol propionate. J. R. Soc. Med. 80 (7), 422–424 (1987).
25. Caesar I, Gross V, Roth M, Andus T, Hohenberger W, Scholmerich J. Steroid-induced myopathy in left-sided ulcerative colitis. Successful treatment and continued therapy with the topical steroid budesonide. Med. Klin. (Munich) 92 (6), 358–362 (1997).
26. Reichert-Penetrat S, Trechot P, Barbaud A, Gillet P, Schmutz JL. Bilateral femoral avascular necrosis in a man with psoriasis: responsibility of topical corticosteroids and role of cyclosporine. Dermatology 203 (4), 356–357 (2001).
27. Sheu HM, Lee JY, Chai CY, Kuo KW. Depletion of stratum corneum intercellular lipid lamellae and barrier function abnormalities after long-term topical corticosteroids. Br. J. Dermatol. 136 (6), 884–890 (1997).
28. Schoepe S, Schacke H, May E, Asadullah K. Glucocorticoid therapy-induced skin atrophy. Exp. Dermatol. 15 (6), 406–420 (2006).
29. Foti C, Bonifazi E, Casulli C, Bonamonte D, Conserva A, Angelini G. Contact allergy to topical corticosteroids in children with atopic dermatitis. Contact Dermatitis 52 (3), 162–163 (2005).
30. Feldman SR. Tachyphylaxis to topical corticosteroids: the more you use them, the less they work? Clin. Dermatol. 24 (3), 229–230 (2006).
31. van Boxtel LA, Hardus PL, Al Hassan WS, van Voorst Vader PC, Jansonium NM. Corticosteroids and the risk of glaucoma. Ned. Tijdschr. Geneeskd. 149 (45), 2485–2489 (2005).
32. Nnoruka E, Okoye O. Topical steroid abuse: its use as a depigmenting agent. J. Natl Med. Assoc. 98 (6), 934–939 (2006).
33. Gathse A, Obengui, Ibara JR. [Reasons for consulting related to skin-bleaching products used by 104 women in Brazzaville]. Bull. Soc. Pathol. Exot. 98 (5), 387–389 (2005).
34. Mahe A, Ly F, Perret JL. Systemic complications of the cosmetic use of skin-bleaching products. Int. J. Dermatol. 44 (Suppl.), 137–138 (2005).
35. de Souza MM. Skin bleaching products in Africa. J. Drugs Dermatol. 4 (2), 144–145 (2005).
36. George AO, Ogunbiyi AO, Daramola OO. Cutaneous adornment in the Yoruba of south-western Nigeria – past and present. Int. J. Dermatol. 45 (1), 23–27 (2006).
37. Malangu N, Ogunbanjo GA. Predictors of topical steroid misuse among patrons of pharmacies in Pretoria. SA Fam. Pract. 48 (1), 14–14e (2006).
38. Wells K, Brodell RT. Topical corticosteroid ‘addiction’: a cause of perioral dermatitis. Postgrad. Med. 93 (5), 225–230 (1993).
39. Oklota CA, Brodell RT. Uncovering tinea incognito. Topical corticosteroids can mask typical features of ringworm. Postgrad. Med. 116 (1), 65–66 (2004).
40. Olumide YM. Abuse of topical steroids in Nigeria. Nigerian Medical Practitioner 11 (1), 7–12 (1986).
41. Sandby-Moller J, Poulsen T, Wulf HC. Epidermal thickness at different body sites: relationship to age, gender, pigmentation, blood content, skin type and smoking habits. Acta. Derm. Venereol. 83 (6), 410–413 (2003).
42. Basak PY, Ozturk M, Baysal V. Assessment of information and education about topical corticosteroids in dermatology outpatient departments: experience from Turkey. J. Eur. Acad. Dermatol. Venereol. 17 (6), 652–658 (2003).
43. Rogers PJ,Wood SM, Garrett EL et al. Use of non prescription topical steroids: patients’experience. Br. J. Dermatol. 152 (6), 1193–1198 (2005).
44. Wahn U, Bos JD, Goodfield M et al. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics 110 (1 Pt 1), e2 (2002).
45. Authoritative facts about the skin from the New Zealand Dermatological Society Inc. www.dermnet.org.nz/disclaimer. html
46. Topical steroids for eczema www. patient.co.uk/showdoc/27000764/
47. National Agency for Food and Drug Administration and Control www.nafdacnigeria.org